Sign up to save your podcasts
Or
Share Pirtobrutinib After Covalent BTK Inhibitor - Double Refractory CLL
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Pirtobrutinib After Covalent BTK Inhibitor - Double Refractory CLL
Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) have poor outcomes after the failure of covalent Bruton's tyrosine kinase (BTK) inhibitor treatment, and new therapeutic options are needed. Pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor, was designed to re-establish BTK inhibition.
View all episodes
By 
4.3
33 ratings
Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) have poor outcomes after the failure of covalent Bruton's tyrosine kinase (BTK) inhibitor treatment, and new therapeutic options are needed. Pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor, was designed to re-establish BTK inhibition.